Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 7/20 | 0.33 |
| ▸ | BACE1 | P56817 | 7/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856082 | 1.00 | CTSD (0.33) | CTSDBACE1PLGGAAEPHX1 | |
| SCHEMBL13685100 | 0.94 | F2 (0.33) | CTSDBACE1PLGGAAEPHX1 | |
| SCHEMBL8289304 | 0.91 | F2 (0.32) | BACE1PLGGAAF2F10 | |
| SCHEMBL8034474 | 0.91 | F2 (0.32) | BACE1PLGGAAF2F10 | |
| SCHEMBL8290280 | 0.89 | BACE1 (0.31) | BACE1PLGGAAF2F10 | |
| SCHEMBL8050876 | 0.89 | BACE1 (0.31) | BACE1PLGGAAF2F10 | |
| SCHEMBL8290536 | 0.89 | GAA (0.33) | BACE1PLGGAAEPHX1F2 | |
| SCHEMBL12608057 | 0.89 | SIRT2 (0.30) | — | |
| SCHEMBL16349734 | 0.88 | GAA (0.35) | BACE1PLGGAAF2F10 | |
| SCHEMBL16349581 | 0.88 | GAA (0.35) | BACE1PLGGAAF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| WO-2005030796-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | CTSD 108/4885BACE1 392/4885PLG 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.